19.51

0.41% -0.08

After Hours: 19.51

Arrivent Biopharma Inc (AVBP)

Overview News Price History Discussions Forecast

Arrivent Biopharma Inc stock is traded at $19.51, with a volume of 250.54K. It is down -0.41% in the last 24 hours and down -10.38% over the past month. ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Previous Close:

$19.59

Open:

$19.49

24h Volume:

250.54K

Relative Volume:

0.78

Market Cap:

$667.49M

Revenue:

Net Income/Loss:

$-81.05M

P/E Ratio:

-7.4375

EPS:

-2.6232

Net Cash Flow:

$-68.97M

1W Performance:

-9.04%

1M Performance:

-10.38%

6M Performance:

-31.64%

1Y Performance:

-10.91%

1-Day Range:

$19.16

$19.82

1-Week Range:

$19.16

$21.50

52-Week Range:

$15.47

$36.37

Arrivent Biopharma Inc Stock (AVBP) Company Profile

Name

Arrivent Biopharma Inc

Sector

Healthcare (1161)

Industry

Biotechnology (646)

Phone

240-780-6356

Address

18 CAMPUS BLVD., NEWTOWN SQUARE

Employee

Twitter

Next Earnings Date

Latest SEC Filings

AVBP's Discussions on Twitter

Compare AVBP with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVBP Arrivent Biopharma Inc	19.51	718.86M	0	-81.05M	-68.97M	-2.6232
VRTX Vertex Pharmaceuticals Inc	456.87	120.48B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	545.46	59.88B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	392.24	44.31B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	670.33	36.65B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	301.13	32.46B	3.81B	-644.79M	-669.77M	-6.24

Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-10-25	Resumed	Goldman	Buy
Mar-20-25	Initiated	B. Riley Securities	Buy
Mar-10-25	Initiated	Guggenheim	Buy
Jul-22-24	Initiated	Oppenheimer	Outperform
Apr-30-24	Initiated	H.C. Wainwright	Buy
Feb-20-24	Initiated	Citigroup	Buy
Feb-20-24	Initiated	Goldman	Buy
Feb-20-24	Initiated	Jefferies	Buy

View All

Arrivent Biopharma Inc Stock (AVBP) Latest News

Jul 31, 2025

What makes ArriVent BioPharma Inc. stock price move sharplyFree Watchlist for Low Risk High Return - Newser

Jul 31, 2025

Tools to monitor ArriVent BioPharma Inc. recovery probabilityDaily Trade Setup Forecast with Confidence - Newser

Jul 31, 2025

Predicting ArriVent BioPharma Inc. trend using moving averagesInsider Strategy for High Conviction Picks - Newser

Jul 31, 2025

Sentiment analysis tools applied to ArriVent BioPharma Inc.Free Strong Buy With Technical Confidence - Newser

Jul 31, 2025

Does ArriVent BioPharma Inc. stock perform well during market downturnsTop Growth Planner For Every Investor - jammulinksnews.com

Jul 31, 2025

Jul 30, 2025

Understanding ArriVent BioPharma Inc.’s price movementSecure Buy Strategy Based on Risk Parameters - Newser

Jul 30, 2025

Trend analysis for ArriVent BioPharma Inc. this weekStable Profit Zone and Loss Control Analysis - Newser

Jul 30, 2025

How ArriVent BioPharma Inc. stock performs during market volatilityFree Expert Verified Stock Trade Ideas - Newser

Jul 30, 2025

Can trapped investors hope for a rebound in ArriVent BioPharma Inc.Weekly Watchlist of High Movers Released - metal.it

Jul 30, 2025

ArriVent BioPharma Inc. stock prediction for this weekFree Smart Trade Plans With Risk Protection - Newser

Jul 30, 2025

Using RSI to spot recovery in ArriVent BioPharma Inc.Free Secure Capital Picks With Upside Potential - Newser

Jul 30, 2025

News impact scoring models applied to ArriVent BioPharma Inc.Price Spike Prediction for Active Traders - Newser

Jul 30, 2025

Jul 29, 2025

ArriVent BioPharma Inc. Earnings Report Breakdown: What Investors Should KnowFree Reliable Alerts for Daily Stock Movers - Newser

Jul 29, 2025

why arrivent biopharma inc. stock attracts strong analyst attentionBuy Point Strategy with Profit Protection - Newser

Jul 29, 2025

Will ArriVent BioPharma Inc. price bounce be sustainableTop Stock Picks with Forecast Accuracy - Newser

Jul 29, 2025

Why ArriVent BioPharma Inc. stock attracts strong analyst attentionTechnical Setup Guide for Daily Watchlist - Newser

Jul 29, 2025

Jul 28, 2025

How Interest Rate Changes Impact ArriVent BioPharma Inc. Stock PerformanceRisk Limited High Gain Trades - metal.it

Jul 28, 2025

Is ArriVent BioPharma Inc. a growth stock or a value stockAchieve consistent double-digit returns - jammulinksnews.com

Jul 28, 2025

Using data models to predict ArriVent BioPharma Inc. stock movementFree Weekly Hot Picks With Buy Confidence - Newser

Jul 28, 2025

ArriVent BioPharma Inc. stock trend forecast Free Reversal Alert Based on RSI Indicator - Newser

Jul 28, 2025

Using data models to predict ArriVent BioPharma Inc. stock movement Low Risk Trade Timing with Analysis Metrics - Newser

Jul 28, 2025

ArriVent BioPharma Inc. recovery potential after sell off Price Action Based Buy Zone Forecast - Newser

Jul 28, 2025

What institutional investors are buying ArriVent BioPharma Inc. stockFree Daily Trading Room Entry - jammulinksnews.com

Jul 28, 2025

Jul 27, 2025

What is ArriVent BioPharma Inc. company’s growth strategyBuild a winning investment strategy - jammulinksnews.com

Jul 27, 2025

How strong is ArriVent BioPharma Inc. company’s balance sheetUnlock real-time stock alerts for quick profits - jammulinksnews.com

Jul 27, 2025

How many analysts rate ArriVent BioPharma Inc. as a “Buy”Exceptional trading performance - jammulinksnews.com

Jul 27, 2025

Is ArriVent BioPharma Inc. stock overvalued or undervaluedAchieve rapid portfolio growth with expert guidance - jammulinksnews.com

Jul 27, 2025

ArriVent BioPharma Inc. Company’s Quarterly Earnings Growth: What the Numbers SaySteady Profit Stock Forecasts - Newser

Jul 27, 2025

Is ArriVent BioPharma Inc. stock a growth or value playLow Risk Trade Timing Signals - Newser

Jul 27, 2025

Jul 26, 2025

ArriVent BioPharma Eyes Early 2026 for Phase 3 Lung Cancer Drug Data - MSN

Jul 26, 2025

Jul 25, 2025

ArriVent BioPharma Inc. Stock Analysis and ForecastExceptional market positioning - PrintWeekIndia

Jul 25, 2025

What risks could impact ArriVent BioPharma Inc. stock performanceLightning-fast capital gains - jammulinksnews.com

Jul 25, 2025

Lifesci Capital Issues Positive Estimate for AVBP Earnings - Defense World

Jul 25, 2025

Jul 24, 2025

Can ArriVent BioPharma Inc. stock recover from recent declineUnprecedented market success - jammulinksnews.com

Jul 24, 2025

What analysts say about ArriVent BioPharma Inc. stockExplosive returns - PrintWeekIndia

Jul 24, 2025

Is ArriVent BioPharma Inc. a good long term investmentPowerful market insights - Autocar Professional

Jul 24, 2025

Jul 23, 2025

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Rating of “Buy” from Analysts - Defense World

Jul 23, 2025